肖文俊,王淼舟

【摘 要】：乳腺癌是女性中最常见且最易感的恶性肿瘤之一，给医疗保健带来了巨大的挑战。许多预后算法被广泛研究和应用，极大地改变了乳腺癌的诊断和治疗策略。本综述主要探讨了乳腺癌预后因素。

【关键词】：乳腺癌;预后因素;恶性肿瘤；病理组织特征；临床因素

[1] Brierley,.D.,Gospodarowicz,M.K.,&Wittekind,C.(Eds.).(2017).TNM classification of malignant tumours.John Wiley&Sons. [2] Rakha,E.A.,Reis-Filho,J.S.,Baehner,F.et al.Breast cancer prognostic classification in the molecular era:the role of histological grade. Breast Cancer Res 12,207(2010). [3] Rakha,E.A.,Reis-Filho,J.S.,Baehner,F.et al.Breast cancer prognostic classification in the molecular era:the role of histological grade. Breast Cancer Res 12,207(2010). [4] Sundquist M,Thorstenson S,Brudin L,Nordenskjold B:Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group.Breast Cancer Res Treat.1999,53:1-8. [5] Frkovic-Grazio S,Bracko M:Long term prognostic value of Nottingham histological grade and its components in early(pT1N0M0)breast carcinoma.J Clin Pathol.2002,55:88-92. [6] Simpson JF,Gray R,Dressler LG,Cobau CD,Falkson CI,Gilchrist KW,Pandya KJ,Page DL,Robert NJ:Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer:results from the Eastern Cooperative Oncology Group Companion Study,EST 4189.J Clin Oncol.2000,18:2059-2069. [7] Rakha EA,El-Sayed ME,Lee AH,Elston CW,Grainge MJ,Hodi Z,Blamey RW,Ellis IO:Prognostic significance of nottingham histologic grade in invasive breast carcinoma.J Clin Oncol.2008,26:3153-3158. [8] Galea MH,Blamey RW,Elston CE,Ellis IO:The Nottingham Prognostic Index in primary breast cancer.Breast Cancer Res Treat. 1992,22:207-219. [9] Wirapati P,Sotiriou C,Kunkel S,Farmer P,Pradervand S,Haibe-Kains B,Desmedt C,Ignatiadis M,Sengstag T,Schütz F,Goldstein DR, Piccart M,Delorenzi M:Meta-analysis of gene expression profiles in breast cancer:toward a unified understanding of breast cancer subtyping and prognosis signatures.Breast Cancer Res.2008,10:R65-10.1186/bcr2124. [10] Mirza AN,Mirza NQ,Vlastos G,Singletary SE:Prognostic factors in node-negative breast cancer:a review of studies with sample size more than 200 and follow-up more than 5 years.Ann Surg.2002,235:10-26. [11] Desmedt C,Haibe-Kains B,Wirapati P,Buyse M,Larsimont D,Bontempi G,Delorenzi M,Piccart M,Sotiriou C:Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.Clin Cancer Res.2008,14:5158-5165. [12] Rakha EA,El-Sayed ME,Green AR,Paish EC,Powe DG,Gee J,Nicholson RI,Lee AH,Robertson JF,Ellis IO:Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.J Clin Oncol.2007,25:4772-4778. [13] Ellis MJ,Tao Y,Luo J,A'Hern R,Evans DB,Bhatnagar AS,Chaudri Ross HA,von Kameke A,Miller WR,Smith I,Eiermann W,Dowsett M:Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.J Natl Cancer Inst.2008,100:1380-1388. [14] Feuer EJ,Wun LM.DEVCAN:Probability of Developing or Dying of Cancer.Version 4.0.National Cancer Institute,MD,USA(1999). [15] Pharoah PD，Day NE，Duffy S，Easton DF，Ponder BA.Family history and the risk of breast cancer:a systematic review and metaanalysis.Int.J.Cancer 71,800–809(1997). [16] Ewertz M,Duffy SW,Adami HO et al.Age at first birth,parity and risk of breast cancer:a meta-analysis of 8 studies from Nordic countries.Int.J.Cancer 46,597–603(1990). [17] Layde PM,Webster LA,Baughman AL,Wingo PA,Rubin GL,Ory HW.The independent associations of parity,age at first full term pregnancy,and duration of breast feeding with the risk of breast cancer.J.Clin.Epidemiol.42,963–973(1989). [18] Collaborative Group on Hormonal Factors in Breast Cancer.Breast cancer and hormone replacement therapy:collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.Lancet 350,1047–1059(1997). [19] Kelsey JL,Gammon MD,John EM.Reproductive factors and breast cancer.Epidemiol.Rev.15,36–47(1993). [20] Rosen PP,Groshen S,Saigo S et al.Pathological prognostic factors in stage I(TIN0M0)and stage II(TINIM0)breast carcinoma:a study of 644 patients with median follow-up of 18 years.J.Clin.Oncol.7,1239–1251(1977). [21] Rosen PP,Groshen S,Saigo S et al.Pathological prognostic factors in stage I(TIN0M0)and stage II(TINIM0)breast carcinoma:a study of 644 patients with median follow-up of 18 years.J.Clin.Oncol.7,1239–1251(1977). [22] Rosen PP,Groshen S,Saigo S et al.Pathological prognostic factors in stage I(TIN0M0)and stage II(TINIM0)breast carcinoma:a study of 644 patients with median follow-up of 18 years.J.Clin.Oncol.7,1239–1251(1977). [23] Rosen PP,Groshen S,Saigo S et al.Pathological prognostic factors in stage I(TIN0M0)and stage II(TINIM0)breast carcinoma:a study of 644 patients with median follow-up of 18 years.J.Clin.Oncol.7,1239–1251(1977). [24] Rosen PP,Groshen S,Saigo S et al.Pathological prognostic factors in stage I(TIN0M0)and stage II(TINIM0)breast carcinoma:a study of 644 patients with median follow-up of 18 years.J.Clin.Oncol.7,1239–1251(1977). [25] Rosen PP,Groshen S,Saigo S et al.Pathological prognostic factors in stage I(TIN0M0)and stage II(TINIM0)breast carcinoma:a study of 644 patients with median follow-up of 18 years.J.Clin.Oncol.7,1239–1251(1977). [26] Roses DF,Bell DA,Flotte TJ,Taylor R,Ratech H,Dubin N.Pathologic predictors of recurrence in stage 1(T1N0M0 and T2N0M0)breast cancer.Am.J.Clin.Pathol.78,817–820(1982). [27] Locker AP,Ellis IO,Morgan DA,Elston CW,Mitchell A,Blamey RW.Factors influencing local recurrence after excision and radiotherapy for primary breast cancer.Br.J.Surg.76,890–894(1989). [28] Kemperman H,Borger J,Hart A,Peterse H,Bartelink H,van Dongen.Prognostic factors for survival after breast conserving therapy for Stage I and II breast cancer;the role of local recurrence.Eur.J.Cancer 31A,690–698(1995). [29] O’Rourke S,Galea MH,Morgan D et al.An audit of local recurrence after simple mastectomy.Br.J.Surg.81,386–389(1994).

点击下载PDF